A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.


Eligibility Criteria:
Inclusion Criteria:

* You must sign an informed consent document for clinical research.
* You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.
* You must not have received any prior treatment for your disease.
* Prior radiation therapy is allowed to \< 25% of the bone marrow; however, prior radiation to the whole pelvis is not allowed. If you have had radiation therapy to the chest, you are not eligible to participate.
* You must be at least 18 years of age or older.
* You must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) or disease can be evaluated on computed tomography (CT) scan.
* Your test results assessing the function of blood forming tissue, kidneys and liver must be satisfactory.
* Women must be sterile, postmenopausal or on contraception and men must be sterile (for example post-vasectomy) or on contraception.

Exclusion Criteria:

* You cannot have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).
* You cannot have Non-small Cell Lung Carcinoma (NSCLC) of predominantly squamous cell histology.
* You cannot have known central nervous system (CNS) disease, other than stable, treated brain metastasis.
* You cannot have undergone a surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days of starting the study treatment, or have an anticipated need for major surgery during the study.
* You cannot have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.
* You are currently receiving ongoing treatment with full-dose warfarin or equivalent.
* You cannot have significant vascular disease, serious cardiac conditions (such as heart attack), stroke or transient ischemic attack within 6 months of the trial.
* You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
* You cannot have inadequately controlled hypertension, or a history of hypertensive crisis or hypertensive encephalopathy.
* You cannot have a serious, nonhealing wound, active ulcer, or untreated bone fracture.
* You cannot have another form of cancer, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.
* You cannot have received an investigational treatment within 30 days prior to the trial.
* You cannot have previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab.
* You cannot be pregnant or breast-feeding.
* You cannot have a known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.
* You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the trial.
* You are unable to stop taking aspirin more than 1.3 grams per day or other nonsteroidal anti-inflammatory drugs (NSAIDs).
* You are unable or unwilling to take folic acid or vitamin B12 supplementation.
* You are unable to take corticosteroids.
* You have any other on-going illnesses including active infections that may not allow you to adhere to the requirements of the trial.